Comparative Pharmacology
Head-to-head clinical analysis: HYDROXYPROGESTERONE CAPROATE versus LEVONORGESTREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXYPROGESTERONE CAPROATE versus LEVONORGESTREL.
HYDROXYPROGESTERONE CAPROATE vs LEVONORGESTREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyprogesterone caproate is a synthetic progestin that acts as an agonist of the progesterone receptor. Its mechanism in preventing preterm birth is not fully understood but may involve suppression of uterine contractility, maintenance of cervical integrity, and modulation of the inflammatory response.
Synthetic progestin that suppresses gonadotropin release (GnRH, LH, FSH) via negative feedback on the hypothalamic-pituitary-ovarian axis; inhibits ovulation, thickens cervical mucus, and alters endometrial lining.
250-500 mg intramuscularly once weekly. For recurrent preterm birth prevention: 250 mg intramuscularly weekly starting at 16-20 weeks gestation until 36 weeks.
For emergency contraception: 1.5 mg orally as a single dose or 0.75 mg orally 12 hours apart. For hormonal contraception: 0.03 mg to 0.05 mg orally once daily in combined oral contraceptives; for progestin-only oral contraceptive (mini-pill): 0.03 mg orally once daily. For intrauterine system (IUD): 52 mg intrauterine device inserted for up to 5 years.
None Documented
None Documented
Clinical Note
moderateHydroxyprogesterone caproate + Digoxin
"Hydroxyprogesterone caproate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateHydroxyprogesterone caproate + Digitoxin
"Hydroxyprogesterone caproate may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateHydroxyprogesterone caproate + Deslanoside
"Hydroxyprogesterone caproate may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateHydroxyprogesterone caproate + Acetyldigitoxin
Terminal elimination half-life is approximately 7-8 days (range 5-14 days) due to slow release from the intramuscular depot, supporting weekly or biweekly dosing.
Terminal half-life: 24-30 hours (range 11-45 hours). This prolonged half-life supports once-daily or extended-cycle dosing in contraceptive formulations.
Primarily renal as metabolites; approximately 50-60% of a dose is excreted in urine within 96 hours, with less than 5% as unchanged drug. Biliary/fecal excretion accounts for approximately 30-40%.
Renal: 45-60% (metabolites), Fecal: 32-45% (unchanged and metabolites). Biliary excretion contributes to fecal elimination.
Category D/X
Category C
Progestin
Progestin
"Hydroxyprogesterone caproate may decrease the cardiotoxic activities of Acetyldigitoxin."